Cargando…
RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A
Hemophilia A is a hemorrhagic disease due to congenital deficiencies of coagulation factor VIII (FVIII). Studies show that hemophilia patients with anticoagulant deficiency present less severe hemorrhagic phenotypes. We aimed to find a new therapeutic option for hemophilia patients by RNA interferen...
Autores principales: | Lin, Wen-yi, Zhu, Ruiqi, Zhang, Zhen, Lu, Xuan, Wang, Huafang, He, Wenjuan, Hu, Yu, Tang, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093307/ https://www.ncbi.nlm.nih.gov/pubmed/33996250 http://dx.doi.org/10.1016/j.omtn.2021.03.022 |
Ejemplares similares
-
Heparin Cofactor II: A Novel Plausible Link of Obesity and Diabetes with Thrombosis
por: Hasegawa, Yutaka, et al.
Publicado: (2017) -
An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B
por: Machin, Nicoletta, et al.
Publicado: (2018) -
Understanding Dermatan Sulfate−Heparin Cofactor II Interaction through Virtual Library Screening
por: Raghuraman, Arjun, et al.
Publicado: (2010) -
MAFLD and ASCVD: Plasma Heparin Cofactor II Activity as an Anti-liver Fibrosis Biomarker
por: Shimabukuro, Michio
Publicado: (2023) -
Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays
por: Kizilocak, Hande, et al.
Publicado: (2019)